Search tips
Search criteria 


Logo of neurotherwww.springer.comThis journalToc AlertsSubmit OnlineOpen Choice
Neurotherapeutics. 2010 October; 7(4): 482–493.
PMCID: PMC2950097

Targeting astrocyte signaling for chronic pain


Clinical management of chronic pain after nerve injury (neuropathic pain) and tumor invasion (cancer pain) is a real challenge due to our limited understanding of the cellular mechanisms that initiate and maintain chronic pain. It has been increasingly recognized that glial cells, such as microglia and astrocytes in the CNS play an important role in the development and maintenance of chronic pain. Notably, astrocytes make very close contacts with synapses and astrocyte reaction after nerve injury, arthritis, and tumor growth is more persistent than microglial reaction, and displays a better correlation with chronic pain behaviors. Accumulating evidence indicates that activated astrocytes can release proinflammatory cytokines (e.g., interleukin [IL]-1β) and chemokines (e.g., monocyte chemoattractant protein-1 [MCP-1]/also called CCL2) in the spinal cord to enhance and prolong persistent pain states. IL-1β can powerfully modulate synaptic transmission in the spinal cord by enhancing excitatory synaptic transmission and suppressing inhibitory synaptic transmission. IL-1β activation (cleavage) in the spinal cord after nerve injury requires the matrix metalloprotease-2. In particular, nerve injury and inflammation activate the c-Jun N-terminal kinase in spinal astrocytes, leading to a substantial increase in the expression and release of MCP-1. The MCP-1 increases pain sensitivity via direct activation of NMDA receptors in dorsal horn neurons. Pharmacological inhibition of the IL-1β, c-Jun N-terminal kinase, MCP-1, or matrix metalloprotease-2 signaling via spinal administration has been shown to attenuate inflammatory, neuropathic, or cancer pain. Therefore, interventions in specific signaling pathways in astrocytes may offer new approaches for the management of chronic pain.

Key Words: Neuropathic pain, nerve injury, spinal cord, cytokine, chemokine, MAP kinase, glia

Contributor Information

Yong-Jing Gao, ude.dravrah.hwb.suez@gnijy.

Ru-Rong Ji, ude.dravrah.hwb.suez@ijrr.


1. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature. 2001;413:203–210. doi: 10.1038/35093019. [PubMed] [Cross Ref]
2. Lundeberg T, Ekholm J. Pain-from periphery to brain. Disabil Rehabil. 2002;24:402–406. doi: 10.1080/09638280110108823. [PubMed] [Cross Ref]
3. Millan MJ. Descending control of pain. Prog Neurobiol. 2002;66:355–474. doi: 10.1016/S0301-0082(02)00009-6. [PubMed] [Cross Ref]
4. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet. 1999;353:1959–1964. doi: 10.1016/S0140-6736(99)01307-0. [PubMed] [Cross Ref]
5. Dubner R, Ruda MA. Activity-dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci. 1992;15:96–103. doi: 10.1016/0166-2236(92)90019-5. [PubMed] [Cross Ref]
6. Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP. Molecular mechanisms of cancer pain. Nat Rev Cancer. 2002;2:201–209. doi: 10.1038/nrc747. [PubMed] [Cross Ref]
7. Willis CL, Davis TP. Chronic inflammatory pain and the neurovascular unit: a central role for glia in maintaining BBB integrity? Curr Pharm Des. 2008;14:1625–1643. doi: 10.2174/138161208784705414. [PubMed] [Cross Ref]
8. Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci. 2009;32:1–32. doi: 10.1146/annurev.neuro.051508.135531. [PMC free article] [PubMed] [Cross Ref]
9. Ji RR, Kohno T, Moore KA, Woolf CJ. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci. 2003;26:696–705. doi: 10.1016/j.tins.2003.09.017. [PubMed] [Cross Ref]
10. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell. 2009;139:267–284. doi: 10.1016/j.cell.2009.09.028. [PMC free article] [PubMed] [Cross Ref]
11. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003;60:1524–1534. doi: 10.1001/archneur.60.11.1524. [PubMed] [Cross Ref]
12. Ho KY, Siau C. Chronic pain management: therapy, drugs and needles. Ann Acad Med Singapore. 2009;38:929–930. [PubMed]
13. Moalem G, Tracey DJ. Immune and inflammatory mechanisms in neuropathic pain. Brain Res Rev. 2006;51:240–264. doi: 10.1016/j.brainresrev.2005.11.004. [PubMed] [Cross Ref]
14. Aldskogius H, Kozlova EN. Central neuron-glial and glial-glial interactions following axon injury. Prog Neurobiol. 1998;55:1–26. doi: 10.1016/S0301-0082(97)00093-2. [PubMed] [Cross Ref]
15. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308:1314–1318. doi: 10.1126/science.1110647. [PubMed] [Cross Ref]
16. Rossi DJ, Brady JD, Mohr C. Astrocyte metabolism and signaling during brain ischemia. Nat Neurosci. 2007;10:1377–1386. doi: 10.1038/nn2004. [PubMed] [Cross Ref]
17. Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10:1387–1394. doi: 10.1038/nn1997. [PubMed] [Cross Ref]
18. Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci. 2007;10:1361–1368. doi: 10.1038/nn1992. [PubMed] [Cross Ref]
19. McMahon SB, Malcangio M. Current challenges in glia-pain biology. Neuron. 2009;64:46–54. doi: 10.1016/j.neuron.2009.09.033. [PubMed] [Cross Ref]
20. Ren K, Dubner R. Neuron-glia crosstalk gets serious: role in pain hypersensitivity. Curr Opin Anaesthesiol. 2008;21:570–579. doi: 10.1097/ACO.0b013e32830edbdf. [PMC free article] [PubMed] [Cross Ref]
21. Hansson E. Could chronic pain and spread of pain sensation be induced and maintained by glial activation? Acta Physiol (Oxf) 2006;187:321–327. doi: 10.1111/j.1748-1716.2006.01568.x. [PubMed] [Cross Ref]
22. Ji RR, Kawasaki Y, Zhuang ZY, Wen YR, Decosterd I. Possible role of spinal astrocytes in maintaining chronic pain sensitization: review of current evidence with focus on bFGF/JNK pathway. Neuron Glia Biol. 2006;2:259–269. doi: 10.1017/S1740925X07000403. [PMC free article] [PubMed] [Cross Ref]
23. Suter MR, Wen YR, Decosterd I, Ji RR. Do glial cells control pain? Neuron Glia Biol. 2007;3:255–268. doi: 10.1017/S1740925X08000100. [PMC free article] [PubMed] [Cross Ref]
24. Watkins LR, Hutchinson MR, Ledeboer A, et al. Norman Cousins Lecture. Glia as the “bad guys”: implications for improving clinical pain control and the clinical utility of opioids. Brain Behav Immun. 2007;21:131–146. doi: 10.1016/j.bbi.2006.10.011. [PMC free article] [PubMed] [Cross Ref]
25. Romero-Sandoval EA, Horvath RJ, DeLeo JA. Neuroimmune interactions and pain: focus on glial-modulating targets. Curr Opin Investig Drugs. 2008;9:726–734. [PMC free article] [PubMed]
26. Hald A. Spinal astrogliosis in pain models: cause and effects. Cell Mol Neurobiol. 2009;29:609–619. doi: 10.1007/s10571-009-9390-6. [PubMed] [Cross Ref]
27. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci. 2009;10:23–36. doi: 10.1038/nrn2533. [PMC free article] [PubMed] [Cross Ref]
28. Halassa MM, Fellin T, Takano H, Dong JH, Haydon PG. Synaptic islands defined by the territory of a single astrocyte. J Neurosci. 2007;27:6473–6477. doi: 10.1523/JNEUROSCI.1419-07.2007. [PubMed] [Cross Ref]
29. Garrison CJ, Dougherty PM, Kajander KC, Carlton SM. Staining of glial fibrillary acidic protein (GFAP) in lumbar spinal cord increases following a sciatic nerve constriction injury. Brain Res. 1991;565:1–7. doi: 10.1016/0006-8993(91)91729-K. [PubMed] [Cross Ref]
30. Colburn RW, Rickman AJ, DeLeo JA. The effect of site and type of nerve injury on spinal glial activation and neuropathic pain behavior. Exp Neurol. 1999;157:289–304. doi: 10.1006/exnr.1999.7065. [PubMed] [Cross Ref]
31. Zhuang ZY, Wen YR, Zhang DR, et al. A peptide c-Jun N-terminal kinase (JNK) inhibitor blocks mechanical allodynia after spinal nerve ligation: respective roles of JNK activation in primary sensory neurons and spinal astrocytes for neuropathic pain development and maintenance. J Neurosci. 2006;26:3551–3560. doi: 10.1523/JNEUROSCI.5290-05.2006. [PubMed] [Cross Ref]
32. Guo W, Wang H, Watanabe M, et al. Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain. J Neurosci. 2007;27:6006–6018. doi: 10.1523/JNEUROSCI.0176-07.2007. [PMC free article] [PubMed] [Cross Ref]
33. Wei F, Guo W, Zou S, Ren K, Dubner R. Supraspinal glial-neuronal interactions contribute to descending pain facilitation. J Neurosci. 2008;28:10482–10495. doi: 10.1523/JNEUROSCI.3593-08.2008. [PMC free article] [PubMed] [Cross Ref]
34. Raghavendra V, Tanga FY, DeLeo JA. Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. Eur J Neurosci. 2004;20:467–473. doi: 10.1111/j.1460-9568.2004.03514.x. [PubMed] [Cross Ref]
35. Sweitzer SM, Colburn RW, Rutkowski M, DeLeo JA. Acute peripheral inflammation induces moderate glial activation and spinal IL-lbeta expression that correlates with pain behavior in the rat. Brain Res. 1999;829:209–221. doi: 10.1016/S0006-8993(99)01326-8. [PubMed] [Cross Ref]
36. Gao YJ, Cheng JK, Zeng Q, et al. Selective inhibition of JNK with a peptide inhibitor attenuates pain hypersensitivity and tumor growth in a mouse skin cancer pain model. Exp Neurol. 2009;219:146–55. doi: 10.1016/j.expneurol.2009.05.006. [PMC free article] [PubMed] [Cross Ref]
37. Fujita M, Andoh T, Ohashi K, et al. Roles of kinin B1 and B2 receptors in skin cancer pain produced by orthotopic melanoma inoculation in mice. Eur J Pain. 2010;14:588–594. doi: 10.1016/j.ejpain.2009.10.010. [PubMed] [Cross Ref]
38. Zhang HW, Iida Y, Andoh T, et al. Mechanical hypersensitivity and alterations in cutaneous nerve fibers in a mouse model of skin cancer pain. J Pharmacol Sci. 2003;91:167–170. doi: 10.1254/jphs.91.167. [PubMed] [Cross Ref]
39. Schwei MJ, Honore P, Rogers SD, et al. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci. 1999;19:10886–10897. [PubMed]
40. Hald A, Nedergaard S, Hansen RR, Ding M, Heegaard AM. Differential activation of spinal cord glial cells in murine models of neuropathic and cancer pain. Eur J Pain. 2009;13:138–145. doi: 10.1016/j.ejpain.2008.03.014. [PubMed] [Cross Ref]
41. Zhang RX, Liu B, Wang L, et al. Spinal glial activation in a new rat model of bone cancer pain produced by prostate cancer cell inoculation of the tibia. Pain. 2005;118:125–136. doi: 10.1016/j.pain.2005.08.001. [PubMed] [Cross Ref]
42. Ma W, Quirion R. Partial sciatic nerve ligation induces increase in the phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) in astrocytes in the lumbar spinal dorsal horn and the gracile nucleus. Pain. 2002;99:175–184. doi: 10.1016/S0304-3959(02)00097-0. [PubMed] [Cross Ref]
43. Zhang J, De Koniuck Y. Spatial and temporal relationship between monocyte chemoattractant protein-1 expression and spinal glial activation following peripheral nerve injury. J Neurochem. 2006;97:772–783. doi: 10.1111/j.1471-4159.2006.03746.x. [PubMed] [Cross Ref]
44. Tanga FY, Raghavendra V, DeLeo JA. Quantitative real-time RT-PCR assessment of spinal microglial and astrocytic activation markers in a rat model of neuropathic pain. Neurochem Int. 2004;45:397–407. doi: 10.1016/j.neuint.2003.06.002. [PubMed] [Cross Ref]
45. Cavaliere C, Cirillo G, Rosaria Bianco M, et al. Gliosis alters expression and uptake of spinal glial amiuo acid transporters in a mouse neuropathic pain model. Neuron Glia Biol. 2007;3:141–153. doi: 10.1017/S1740925X07000695. [PubMed] [Cross Ref]
46. Svensson M, Eriksson NP, Aldskogius H. Evidence for activation of astrocytes via reactive microglial cells following hypoglossal nerve transection. J Neurosci Res. 1993;35:373–381. doi: 10.1002/jnr.490350404. [PubMed] [Cross Ref]
47. Miyoshi K, Obata K, Kondo T, Okamura H, Noguchi K. Interleukin-18-mediated microglia/astrocyte interaction in the spinal cord enhances neuropathic pain processing after nerve injury. J Neurosci. 2008;28:12775–12787. doi: 10.1523/JNEUROSCI.3512-08.2008. [PubMed] [Cross Ref]
48. Garrison CJ, Dougherty PM, Carlton SM. GFAP expression in lumbar spinal cord of naive and neuropathic rats treated with MK-801. Exp Neurol. 1994;129:237–243. doi: 10.1006/exnr.1994.1165. [PubMed] [Cross Ref]
49. Chen JJ, Lue JH, Lin LH, et al. Effects of pre-emptive drug treatment on astrocyte activation in the cuneate nucleus following rat median nerve injury. Pain. 2010;148:158–166. doi: 10.1016/j.pain.2009.11.004. [PubMed] [Cross Ref]
50. Colburn RW, DeLeo JA, Rickman AJ, et al. Dissociation of microglial activation and neuropathic pain behaviors following peripheral nerve injury in the rat. J Neuroimmnunol. 1997;79:163–175. doi: 10.1016/S0165-5728(97)00119-7. [PubMed] [Cross Ref]
51. Kim DS, Figueroa KW, Li KW, et al. Profiling of dynamically changed gene expression in dorsal root ganglia post peripheral nerve injury and a critical role of injury-induced glial fibrillary acidic protein in maintenance of pain behaviors [corrected] Pain. 2009;143:114–122. doi: 10.1016/j.pain.2009.02.006. [PMC free article] [PubMed] [Cross Ref]
52. Gao YJ, Zhang L, Samad OA, et al. JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain. J Neurosci. 2009;29:4096–4108. doi: 10.1523/JNEUROSCI.3623-08.2009. [PMC free article] [PubMed] [Cross Ref]
53. Weyerbacher AR, Xu Q, Tamasdan C, Shin SJ, Inturrisi CE. N-Methyl-D-aspartate receptor (NMDAR) independent maintenance of inflammatory pain. Pain. 2010;148:237–246. doi: 10.1016/j.pain.2009.11.003. [PMC free article] [PubMed] [Cross Ref]
54. Svensson CI, Brodin E. Spinal astrocytes in pain processing: non-neuronal cells as therapeutic targets. Mol Interv. 2010;10:25–38. doi: 10.1124/mi.10.1.6. [PubMed] [Cross Ref]
55. Svensson CI, Zattoni M, Serhan CN. Lipoxius and aspirin-triggered lipoxin inhibit inflammatory pain processing. J Exp Med. 2007;204:245–252. doi: 10.1084/jem.20061826. [PMC free article] [PubMed] [Cross Ref]
56. Gao YJ, Xu ZZ, Liu YC, et al. The c-Jun N-terminal kinase 1 (JNK1) in spinal astrocytes is required for the maintenance of bilateral mechanical allodynia under a persistent inflammatory pain condition. Pain. 2010;148:309–319. doi: 10.1016/j.pain.2009.11.017. [PMC free article] [PubMed] [Cross Ref]
57. Hofstetter CP, Holmstrom NA, Lilja JA, et al. Allodynia limits the usefulness of intraspinal neural stem cell grafts; directed differentiation improves outcome. Nat Neurosci. 2005;8:346–353. doi: 10.1038/nn1405. [PubMed] [Cross Ref]
58. Davies JE, Proschel C, Zhang N, et al. Transplanted astrocytes derived from BMP- or CNTF-treated glial-restricted precursors have opposite effects on recovery and allodynia after spinal cord injury. J Biol. 2008;7:24–24. doi: 10.1186/jbiol85. [PMC free article] [PubMed] [Cross Ref]
59. Gao YJ, Zhang L, Ji RR. Spinal injection of TNF-α-activated astrocytes produces persistent pain symptom-mechanical allodynia by releasing monocyte chemoattractant protein-1. Glia 2010 (in press). [PMC free article] [PubMed]
60. Meiler ST, Dykstra C, Grzybycki D, Murphy S, Gebhart GF. The possible role of glia in nociceptive processing and hyperalgesia in the spinal cord of the rat. Neuropharmacology. 1994;33:1471–1478. doi: 10.1016/0028-3908(94)90051-5. [PubMed] [Cross Ref]
61. Watkius LR, Martin D, Ulrich P, Tracey KJ, Maier SF. Evidence for the involvement of spinal cord glia in subcutaneous formalin induced hyperalgesia in the rat. Pain. 1997;71:225–235. doi: 10.1016/S0304-3959(97)03369-1. [PubMed] [Cross Ref]
62. Milligan ED, Twining C, Chacur M, et al. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci. 2003;23:1026–1040. [PubMed]
63. Obata H, Eisenach JC, Hussain H, Bynum T, Vincier M. Spinal glial activation contributes to postoperative mechanical hypersensitivity in the rat. J Pain. 2006;7:816–822. doi: 10.1016/j.jpain.2006.04.004. [PubMed] [Cross Ref]
64. Clark AK, Gentry C, Bradbury EJ, McMahon SB, Malcangio M. Role of spinal microglia in rat models of peripheral nerve injury and inflammation. Eur J Pain. 2007;11:223–230. doi: 10.1016/j.ejpain.2006.02.003. [PubMed] [Cross Ref]
65. Okada-Ogawa A, Suzuki I, Sessle BJ, et al. Astroglia in medullary dorsal horn (trigeminal spinal subnucleus caudalis) are involved in trigeminal neuropathic pain mechanisms. J Neurosci. 2009;29:11161–11171. doi: 10.1523/JNEUROSCI.3365-09.2009. [PMC free article] [PubMed] [Cross Ref]
66. Ledeboer A, Mahoney JH, Milligan ED, et al. Spinal cord glia and interleukin-1 do not appear to mediate persistent allodynia induced by intramuscular acidic saline in rats. J Pain. 2006;7:757–767. doi: 10.1016/j.jpain.2006.04.001. [PubMed] [Cross Ref]
67. Huck S, Grass F, Hortnagl H. The glutamate analogue alpha-aminoadipic acid is taken up by astrocytes before exerting its gliotoxic effect in vitro. J Neurosci. 1984;4:2650–2657. [PubMed]
68. Khurgel M, Koo AC, Ivy GO. Selective ablation of astrocytes by intracerebral injections of alpha-aminoadipate. Glia. 1996;16:351–358. doi: 10.1002/(SICI)1098-1136(199604)16:4<351::AID-GLIA7>3.0.CO;2-2. [PubMed] [Cross Ref]
69. Rodriguez MJ, Martinez-Sanchez M, Bernal F, Mahy N. Heterogeneity between hippocampal and septal astroglia as a contributing factor to differential in vivo AMPA excitotoxicity. J Neurosci Res. 2004;77:344–353. doi: 10.1002/jnr.20177. [PubMed] [Cross Ref]
70. Wang W, Wang W, Mei X, et al. Crosstalk between spinal astrocytes and neurons in nerve injury-induced neuropathic pain. PLoS One. 2009;4:e6973–e6973. doi: 10.1371/journal.pone.0006973. [PMC free article] [PubMed] [Cross Ref]
71. Beart PM, O’Shea RD. Transporters for L-glutamate: an update on their molecular pharmacology and pathological involvement. Br J Pharmacol. 2007;150:5–17. doi: 10.1038/sj.bjp.0706949. [PMC free article] [PubMed] [Cross Ref]
72. Huang YH, Bergles DE. Glutamate transporters bring competition to the synapse. Curr Opin Neurobiol. 2004;14:346–352. doi: 10.1016/j.conb.2004.05.007. [PubMed] [Cross Ref]
73. Tawfik VL, Lacroix-Fralish ML, Bercury KK, et al. Induction of astrocyte differentiation by propentofylline increases glutamate transporter expression in vitro: heterogeneity of the quiescent phenotype. Glia. 2006;54:193–203. doi: 10.1002/glia.20365. [PubMed] [Cross Ref]
74. Rothstein JD, Dykes-Hoberg M, Pardo CA, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron. 1996;16:675–686. doi: 10.1016/S0896-6273(00)80086-0. [PubMed] [Cross Ref]
75. Tanaka K, Watase K, Manabe T, et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science. 1997;276:1699–702. doi: 10.1126/science.276.5319.1699. [PubMed] [Cross Ref]
76. Katagiri H, Tanaka K, Manabe T. Requirement of appropriate glutamate concentrations in the synaptic cleft for hippocampal LTP induction. Eur J Neurosci. 2001;14:547–553. doi: 10.1046/j.0953-816x.2001.01664.x. [PubMed] [Cross Ref]
77. Levenson J, Weeber E, Selcher JC, et al. Long-term potentiation and contextual fear conditioning increase neuronal glutamate uptake. Nat Neurosci. 2002;5:155–161. doi: 10.1038/nn791. [PubMed] [Cross Ref]
78. Sung B, Lim G, Mao J. Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats. J Neurosci. 2003;23:2899–2910. [PubMed]
79. Wang W, Wang W, Wang Y, et al. Temporal changes of astrocyte activation and glutamate transporter-1 expression in the spinal cord after spinal nerve ligation-induced neuropathic pain. Anat Rec (Hoboken) 2008;291:513–518. [PubMed]
80. Xin WJ, Weng HR, Dougherty PM. Plasticity in expression of the glutamate transporters GLT-1 and GLAST in spinal dorsal horn glial cells following partial sciatic nerve ligation. Mol Pain. 2009;5:15–15. doi: 10.1186/1744-8069-5-15. [PMC free article] [PubMed] [Cross Ref]
81. Tawfik VL, Regan MR, Haenggeli C, et al. Propentofylline-induced astrocyte modulation leads to alterations in glial glutamate promoter activation following spinal nerve transection. Neuroscience. 2008;152:1086–1092. doi: 10.1016/j.neuroscience.2008.01.065. [PMC free article] [PubMed] [Cross Ref]
82. Liaw WJ, Stephens RL, Binns BC, et al. Spinal glutamate uptake is critical for maintaining normal sensory transmission in rat spinal cord. Pain. 2005;115:60–70. doi: 10.1016/j.pain.2005.02.006. [PubMed] [Cross Ref]
83. Weng HR, Chen JH, Cata JP. Inhibition of glutamate uptake in the spinal cord induces hyperalgesia and increased responses of spinal dorsal horn neurons to peripheral afferent stimulation. Neuroscience. 2006;138:1351–1360. doi: 10.1016/j.neuroscience.2005.11.061. [PubMed] [Cross Ref]
84. Maeda S, Kawamoto A, Yatani Y, et al. Gene transfer of GLT-1, a gliai glutamate transporter, into the spinal cord by recombinant adenovirus attenuates inflammatory and neuropathic pain in rats. Mol Pain. 2008;4:65–65. doi: 10.1186/1744-8069-4-65. [PMC free article] [PubMed] [Cross Ref]
85. Chiang CY, Wang J, Xie YF, et al. Astroglial glutamate-glutamine shuttle is involved in central sensitization of nociceptive neurons in rat medullary dorsal horn. J Neurosci. 2007;27:9068–76. doi: 10.1523/JNEUROSCI.2260-07.2007. [PubMed] [Cross Ref]
86. Kozai T, Yamanaka H, Dai Y, et al. Tissue type plasminogen activator induced in rat dorsal horn astrocytes contributes to mechanical hypersensitivity following dorsal root injury. Glia. 2007;55:595–603. doi: 10.1002/glia.20483. [PubMed] [Cross Ref]
87. Bruno MA, Cuello AC. Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proc Natl Acad Sci U S A. 2006;103:6735–6740. doi: 10.1073/pnas.0510645103. [PubMed] [Cross Ref]
88. Pang PT, Teng HK, Zaitsev E, et al. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science. 2004;306:487–491. doi: 10.1126/science.1100135. [PubMed] [Cross Ref]
89. Hoffman KB, Martinez J, Lynch G. Proteolysis of cell adhesion molecules by serine proteases: a role in long term potentiation? Brain Res. 1998;811:29–33. doi: 10.1016/S0006-8993(98)00906-8. [PubMed] [Cross Ref]
90. Qian Z, Gilbert ME, Colicos MA, Kandel ER, Kuhl D. Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature. 1993;361:453–457. doi: 10.1038/361453a0. [PubMed] [Cross Ref]
91. Blomstrand F, Khatibi S, Muyderman H, et al. 5-Hydroxytryptamine and glutamate modulate velocity and extent of intercellular calcium signalling in hippocampal astroglial cells in primary cultures. Neuroscience. 1999;88:1241–1253. doi: 10.1016/S0306-4522(98)00351-0. [PubMed] [Cross Ref]
92. Haydon PG. GLIA: listening and talking to the synapse. Nat Rev Neurosci. 2001;2:185–193. doi: 10.1038/35058528. [PubMed] [Cross Ref]
93. Giaume C, McCarthy KD. Control of gap-junctional communication in astrocytic networks. Trends Neurosci. 1996;19:319–325. doi: 10.1016/0166-2236(96)10046-1. [PubMed] [Cross Ref]
94. Nagy JI, Dudek FE, Rash JE. Update on connexins and gap junctions in neurons and glia in the mammalian nervous system. Brain Res Brain Res Rev. 2004;47:191–215. doi: 10.1016/j.brainresrev.2004.05.005. [PubMed] [Cross Ref]
95. Rohlmann A, Laskawi R, Hofer A, et al. Facial nerve lesions lead to increased immunostaining of the astrocytic gap junction protein (connexin 43) in the corresponding facial nucleus of rats. Neurosci Lett. 1993;154:206–208. doi: 10.1016/0304-3940(93)90208-3. [PubMed] [Cross Ref]
96. Lee IH, Lindqvist E, Kiehn O, Widenfalk J, Olson L. Glial and neuronal connexin expression patterns in the rat spinal cord during development and following injury. J Comp Neurol. 2005;489:1–10. doi: 10.1002/cne.20567. [PubMed] [Cross Ref]
97. Qin M, Wang JJ, Cao R, et al. The lumbar spinal cord glial cells actively modulate subcutaneous formalin induced hyperalgesia in the rat. Neurosci Res. 2006;55:442–450. doi: 10.1016/j.neures.2006.04.017. [PubMed] [Cross Ref]
98. Spataro LE, Sloane EM, Milligan ED, et al. Spinal gap junctions: potential involvement in pain facilitation. J Pain. 2004;5:392–405. doi: 10.1016/j.jpain.2004.06.006. [PubMed] [Cross Ref]
99. Lan L, Yuan H, Duau L, et al. Blocking the glial function suppresses subcutaneous formalin-induced nociceptive behavior in he rat. Neurosci Res. 2007;57:112–129. doi: 10.1016/j.neures.2006.09.014. [PubMed] [Cross Ref]
100. Zhuang ZY, Gerner P, Woolf CJ, Ji RR. ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain. 2005;114:149–159. doi: 10.1016/j.pain.2004.12.022. [PubMed] [Cross Ref]
101. Peters CM, Rogers SD, Pomonis JD, et al. Endothelin receptor expression in the normal and injured spinal cord: potential involvement in injury-induced ischemia and gliosis. Exp Neurol. 2003;180:1–13. doi: 10.1016/S0014-4886(02)00023-7. [PubMed] [Cross Ref]
102. Madiai F, Goettl VM, Hussain SR, et al. Anti-fibroblast growth factor-2 antibodies attenuate mechanical allodynia in a rat model of neuropathic pain. J Mol Neurosci. 2005;27:315–324. doi: 10.1385/JMN:27:3:315. [PubMed] [Cross Ref]
103. Madiai F, Hussain SR, Goettl VM, et al. Upregulation of FGF-2 in reactive spinal cord astrocytes following unilateral lumbar spinal nerve ligation. Exp Brain Res. 2003;148:366–376. [PubMed]
104. Garry EM, Delaney A, Blackburn-Munro G, et al. Activation of p38 and p42/44 MAP kinase in neuropathic pain: involvement of VPAC2 and NK2 receptors and mediation by spinal glia. Mol Cell Neurosci. 2005;30:523–537. doi: 10.1016/j.mcn.2005.08.016. [PubMed] [Cross Ref]
105. Knerlich-Lukoschus F, Juraschek M, Blomer U, et al. Force-dependent development of neuropathic central pain and time-related CCL2/CCR2 expression after graded spinal cord contusion injuries of the rat. J Neurotrauma. 2008;25:427–448. doi: 10.1089/neu.2007.0431. [PubMed] [Cross Ref]
106. Kawasaki Y, Zhang L, Cheng JK, Ji RR. Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1beta, iuterleukin-6, and tumor necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord. J Neurosci. 2008;28:5189–5194. doi: 10.1523/JNEUROSCI.3338-07.2008. [PMC free article] [PubMed] [Cross Ref]
107. Zhang RX, Li A, Liu B, et al. IL-1ra alleviates inflammatory hyperalgesia through preventing phosphorylation of NMDA receptor NR-1 subunit in rats. Pain. 2008;135:232–239. doi: 10.1016/j.pain.2007.05.023. [PMC free article] [PubMed] [Cross Ref]
108. DeLeo JA, Colburn RW, Rickman AJ. Cytokine and growth factor immunohistochemical spinal profiles in two animal models of mononeuropathy. Brain Res. 1997;759:50–57. doi: 10.1016/S0006-8993(97)00209-6. [PubMed] [Cross Ref]
109. Fu D, Guo Q, Ai Y, et al. Glial activation and segmental upregulation of interleukin-lbeta (IL-1beta) in the rat spinal cord after surgical incision. Neurochein Res. 2006;31:333–340. doi: 10.1007/s11064-005-9032-4. [PubMed] [Cross Ref]
110. Milligan ED, O’Connor KA, Nguyen KT, et al. Intrathecal HIV-1 envelope glycoprotein gp120 induces enhanced pain states mediated by spinal cord proinflammatory cytokines. J Neurosci. 2001;21:2808–2819. [PubMed]
111. Sweitzer S, Martin D, DeLeo JA. Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain. Neuroscience. 2001;103:529–539. doi: 10.1016/S0306-4522(00)00574-1. [PubMed] [Cross Ref]
112. Wolf G, Gabay E, Tal M, Yirmiya R, Shavit Y. Genetic impairment of interleukin-1 signaling attenuates neuropathic pain, autotomy, and spontaneous ectopic neuronal activity, following nerve injury in mice. Pain. 2006;120:315–324. doi: 10.1016/j.pain.2005.11.011. [PubMed] [Cross Ref]
113. Ji GC, Zhang YQ, Ma F, Wu GC. Increase of nociceptive threshold induced by intrathecal injection of interleukin-1 beta in normal and carrageenan inflammatory rat. Cytokine. 2002;19:31–36. doi: 10.1006/cyto.2002.1949. [PubMed] [Cross Ref]
114. Kawasaki Y, Xu ZZ, Wang X, et al. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat Med. 2008;14:331–336. doi: 10.1038/nm1723. [PMC free article] [PubMed] [Cross Ref]
115. Tadano T, Namioka M, Nakagawasai O, et al. Induction of nociceptive responses by intrathecal injection of interleukin-1 in mice. Life Sci. 1999;65:255–261. doi: 10.1016/S0024-3205(99)00244-1. [PubMed] [Cross Ref]
116. Sung CS, Wen ZH, Chang WK, et al. Intrathecal interleukin-1beta administration induces thermal hyperalgesia by activating inducible nitric oxide synthase expression in the rat spinal cord. Brain Res. 2004;1015:145–153. doi: 10.1016/j.brainres.2004.04.068. [PubMed] [Cross Ref]
117. Reeve AJ, Patel S, Fox A, Walker K, Urban L. Intrathecally administered endotoxin or cytokines produce allodynia, hyperalgesia and changes in spinal cord neuronal responses to nociceptive stimuli in the rat. Eur J Pain. 2000;4:247–257. doi: 10.1053/eujp.2000.0177. [PubMed] [Cross Ref]
118. Tsakiri N, Kimber I, Rothwell NJ, Pinteaux E. Interleukin-1-induced interleukin-6 synthesis is mediated by the neutral sphingomyelinase/Src kinase pathway in neurones. Br J Pharmacol. 2008;153:775–783. doi: 10.1038/sj.bjp.0707610. [PMC free article] [PubMed] [Cross Ref]
119. Zhang RX, Liu B, Li A, et al. Interleukin 1beta facilitates bone cancer pain in rats by enhancing NMDA receptor NR-1 subunit phosphorylation. Neuroscience. 2008;154:1533–1558. doi: 10.1016/j.neuroscience.2008.04.072. [PMC free article] [PubMed] [Cross Ref]
120. Binshtok AM, Wang H, Zimmermann K, et al. Nociceptors are interleukin-1beta sensors. J Neurosci. 2008;28:14062–14073. doi: 10.1523/JNEUROSCI.3795-08.2008. [PMC free article] [PubMed] [Cross Ref]
121. Coull JA, Beggs S, Boudreau D, et al. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature. 2005;438:1017–1021. doi: 10.1038/nature04223. [PubMed] [Cross Ref]
122. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science. 2000;288:1765–1769. doi: 10.1126/science.288.5472.1765. [PubMed] [Cross Ref]
123. Samad TA, Moore KA, Sapirstein A, et al. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature. 2001;410:471–475. doi: 10.1038/35068566. [PubMed] [Cross Ref]
124. Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia. 2002;39:279–291. doi: 10.1002/glia.10108. [PubMed] [Cross Ref]
125. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol. 2004;4:617–629. doi: 10.1038/nri1418. [PubMed] [Cross Ref]
126. Yong VW. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci. 2005;6:931–944. doi: 10.1038/nrn1807. [PubMed] [Cross Ref]
127. Manicone AM, McGuire JK. Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol. 2008;19:34–41. doi: 10.1016/j.semcdb.2007.07.003. [PMC free article] [PubMed] [Cross Ref]
128. Schonbeck U, Mach F, Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol. 1998;161:3340–3346. [PubMed]
129. Croitoru-Lamoury J, Guillemin GJ, Boussin FD, et al. Expression of chemokines and their receptors in human and simian astrocytes: evidence for a central role of TNF alpha and IFN gamma in CXCR4 and CCR5 modulation. Glia. 2003;41:354–370. doi: 10.1002/glia.10181. [PubMed] [Cross Ref]
130. Meeuwsen S, Persoon-Deen C, Bsibsi M, Ravid R, van Noort JM. Cytokine, chemokine and growth factor gene profiling of cultured human astrocytes after exposure to proinflammatory stimuli. Glia. 2003;43:243–253. doi: 10.1002/glia.10259. [PubMed] [Cross Ref]
131. El-Hage N, Gurwell JA, Singh IN, et al. Synergistic increases in intracellular Ca2+, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat. Glia. 2005;50:91–106. doi: 10.1002/glia.20148. [PMC free article] [PubMed] [Cross Ref]
132. Mojsilovic-Petrovic J, Callaghan D, Cui H, et al. Hypoxia-inducible factor-1 (HIF-1) is involved in the regulation of hypoxia-stimulated expression of monocyte chemoattractant protein-1 (MCP-1/CCL2) and MCP-5 (Cell2) in astrocytes. J Neuroinflammation. 2007;4:12–12. doi: 10.1186/1742-2094-4-12. [PMC free article] [PubMed] [Cross Ref]
133. Van Der Voorn P, Tekstra J, Beelen RH, et al. Expression of MCP-1 by reactive astrocytes in demyelinating multiple, sclerosis lesions. Am J Pathol. 1999;154:45–51. doi: 10.1016/S0002-9440(10)65249-2. [PubMed] [Cross Ref]
134. Tanuma N, Sakuma H, Sasaki A, Matsumoto Y. Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis. Acta Neuropathol. 2006;112:195–204. doi: 10.1007/s00401-006-0083-7. [PubMed] [Cross Ref]
135. Huang D, Han Y, Rani MR, et al. Chemokines and chemokine receptors in inflammation of the nervous system: manifold roles and exquisite regulation. Immunol Rev. 2000;177:52–67. doi: 10.1034/j.1600-065X.2000.17709.x. [PubMed] [Cross Ref]
136. Babcock AA, Kuziel WA, Rivest S, Owens T. Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J Neurosci. 2003;23:7922–7930. [PubMed]
137. Yan YP, Sailor KA, Lang BT, et al. Monocyte chemoattractant protein-1 plays a critical role in neuroblast migration after focal cerebral ischemia. J Cereb Blood Flow Metab. 2007;27:1213–1224. doi: 10.1038/sj.jcbfm.9600432. [PubMed] [Cross Ref]
138. White FA, Sun J, Waters SM, et al. Excitatory monocyte chemoattractant protein-1 signaling is up-regulated in sensory neurons after chronic compression of the dorsal root ganglion. Proc Natl Acad Sci U S A. 2005;102:14092–14097. doi: 10.1073/pnas.0503496102. [PubMed] [Cross Ref]
139. Gosseliu RD, Varela C, Banisadr G, et al. Constitutive expression of CCR2 chemokine receptor and inhibition by MCP-1/CCL2 of GABA-induced currents in spinal cord neurones. J Neurochem. 2005;95:1023–1034. doi: 10.1111/j.1471-4159.2005.03431.x. [PubMed] [Cross Ref]
140. Gao YJ, Ji RR. c-Fos and pERK, which is a better marker for neuronal activation and central sensitization after noxious stimulation and tissue injury? Open Pain J. 2009;2:11–7. doi: 10.2174/1876386300902010011. [PMC free article] [PubMed] [Cross Ref]
141. Thacker MA, Clark AK, Bishop T, et al. CCL2 is a key mediator of microglia activation in neuropathic pain states. Eur J Pain. 2009;13:263–272. doi: 10.1016/j.ejpain.2008.04.017. [PubMed] [Cross Ref]
142. Abbadie C, Lindia JA, Cumiskey AM, et al. Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc Natl Acad Sci U S A. 2003;100:7947–7952. doi: 10.1073/pnas.1331358100. [PubMed] [Cross Ref]
143. Zhang J, Shi XQ, Echeverry S, et al. Expression of CCR2 in both resident and bone marrow-derived microglia plays a critical role in neuropathic pain. J Neurosci. 2007;27:12396–12406. doi: 10.1523/JNEUROSCI.3016-07.2007. [PubMed] [Cross Ref]
144. Bhangoo S, Ren D, Miller RJ, et al. Delayed functional expression of neuronal chemokine receptors following focal nerve demyelination in the rat: a mechanism for the development of chronic sensitization of peripheral nociceptors. Mol Pain. 2007;3:38–38. doi: 10.1186/1744-8069-3-38. [PMC free article] [PubMed] [Cross Ref]
145. Bhangoo SK, Ripsch MS, Buchanan DJ, Miller RJ, White FA. Increased chemokine signaling in a model of HIV1-associated peripheral neuropathy. Mol Pain. 2009;5:48–48. doi: 10.1186/1744-8069-5-48. [PMC free article] [PubMed] [Cross Ref]
146. Ji RR, Gereau RWt, Malcangio M, Strichartz GR. MAP kinase and pain. Brain Res Rev. 2009;60:135–148. doi: 10.1016/j.brainresrev.2008.12.011. [PMC free article] [PubMed] [Cross Ref]
147. Jin SX, Zhuang ZY, Woolf CJ, Ji RR. p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci. 2003;23:4017–4022. [PubMed]
148. Tsuda M, Mizokoshi A, Shigemoto-Mogami Y, Koizumi S, Inoue K. Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury. Glia. 2004;45:89–95. doi: 10.1002/glia.10308. [PubMed] [Cross Ref]
149. Weyerbacher AR, Xu Q, Tamasdan C, Shin SJ, Inturrisi CE. N-Methyl-d-aspartate receptor (NMDAR) independent maintenance of inflammatory pain. Pain. 2010;148:237–246. doi: 10.1016/j.pain.2009.11.003. [PMC free article] [PubMed] [Cross Ref]
150. Migheli A, Piva R, Atzori C, Troost D, Schiffer D. c-Jun, JNK/ SAPK kinases and transcription factor NF-kappa B are selectively activated in astrocytes, but not motor neurons, in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 1997;56:1314–1322. doi: 10.1097/00005072-199712000-00006. [PubMed] [Cross Ref]
151. Obata K, Yamanaka H, Kobayashi K, et al. Role of mitogenactivated protein kinase activation in injured and intact primary afferent neurons for mechanical and heat hypersensitivity after spinal nerve ligation. J Neurosci. 2004;24:10211–10222. doi: 10.1523/JNEUROSCI.3388-04.2004. [PubMed] [Cross Ref]
152. Daulhac L, Mallet C, Courteix C, et al. Diabetes-induced mechanical hyperalgesia involves spinal mitogen-activated protein kinase activation in neurons and microglia via N-rnetbyl-D-aspartate~dependent mechanisms. Mol Pharmacol. 2006;70:1246–1254. doi: 10.1124/mol.106.025478. [PubMed] [Cross Ref]
153. Falsig J, Porzgen P, Lotharius J, Leist M. Specific modulation of astrocyte inflammation by inhibition of mixed lineage kinases with CEP-1347. J Immunol. 2004;173:2762–2770. [PubMed]
154. Gao YJ, Ji RR. Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol Ther. 2010;126:56–68. doi: 10.1016/j.pharmthera.2010.01.002. [PMC free article] [PubMed] [Cross Ref]
155. Katsura H, Obata K, Miyoshi K, et al. Transforming growth factor-activated kinase 1 induced in spinal astrocytes contributes to mechanical hypersensitivity after nerve injury. Glia. 2008;56:723–733. doi: 10.1002/glia.20648. [PubMed] [Cross Ref]
156. Ferrara N, Ousley F, Gospodarowicz D. Bovine brain astrocytes express basic fibroblast growth factor, a neurotropic and angiogenic mitogen. Brain Res. 1988;462:223–232. doi: 10.1016/0006-8993(88)90550-1. [PubMed] [Cross Ref]
157. Eclancher F, Perraud F, Faltin J, Labourdette G, Sensenbrenner M. Reactive astrogliosis after basic fibroblast growth factor (bFGF) injection in injured neonatal rat brain. Glia. 1990;3:502–509. doi: 10.1002/glia.440030609. [PubMed] [Cross Ref]
158. Takano T, Oberheim N, Cotrina ML, Nedergaard M. Astrocytes and ischemic injury. Stroke. 2009;40:S8–S12. doi: 10.1161/STROKEAHA.108.533166. [PMC free article] [PubMed] [Cross Ref]
159. Hayakawa K, Nakano T, Irie K, et al. Inhibition of reactive astrocytes with fluorocitrate retards neurovascular remodeling and recovery after focal cerebral ischemia in mice. J Cereb Blood Flow Metab. 2010;30:871–882. doi: 10.1038/jcbfm.2009.257. [PMC free article] [PubMed] [Cross Ref]
160. Borsello T, Clarke PG, Hirt L, et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med. 2003;9:1180–1186. doi: 10.1038/nm911. [PubMed] [Cross Ref]
161. Davis JE, Gabler NK, Walker-Daniels J, Spurlock ME. The c-Jun N-terminal kinase mediates the induction of oxidative stress and insulin resistance by palmitate and toll-like receptor 2 and 4 ligands in 3T3-L1 adipocytes. Florin Metab Res. 2009;41:523–530. doi: 10.1055/s-0029-1202852. [PubMed] [Cross Ref]
162. Ijaz A, Tejada T, Catanuto P, et al. Inhibition of C-jun N-terminal kinase improves insulin sensitivity but worsens albuminuria in experimental diabetes. Kidney Int. 2009;75:381–388. doi: 10.1038/ki.2008.559. [PubMed] [Cross Ref]
163. Oberheim NA, Takano T, Han X, et al. Uniquely hominid features of adult human astrocytes. J Neurosci. 2009;29:3276–3287. doi: 10.1523/JNEUROSCI.4707-08.2009. [PMC free article] [PubMed] [Cross Ref]
164. Oberheim NA, Wang X, Goldman S, Nedergaard M. Astrocytic complexity distinguishes the human brain. Trends Neurosci. 2006;29:547–553. doi: 10.1016/j.tins.2006.08.004. [PubMed] [Cross Ref]

Articles from Neurotherapeutics are provided here courtesy of Springer